Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DGPR1008 for intraoperative imaging in prostate cancer (Phase II)
CTR20260305Phase 2Active
- Sponsor
- Xindou Biotechnology
- Start
- Mar 2026
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DGPR1008 in prostate cancer (PCa), sponsored by Xindou Biotechnology. Primary endpoints: Sensitivity and specificity of DGPR1008 in detecting prostate cancer tissue by near-infrared fluorescence imaging during radical prostatectomy at different time windows and Proportion of additional resected fluorescent tumor bed tissues that are pathologically tumor-positive. Started Mar 2026; status: active.
02
Drugs
DGPR1008
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20260305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260305.